Beacon NewsFlashes – January 9, 2009
Milestones In Myeloma – The Leukemia & Lymphoma Society (LLS) will hold a dinner program on January 13, 2009, from 6:30 p.m. to 8:30 p.m. at Johnny Carino’s restaurant in Austin, TX. Guest speaker Dr. Punit Chadha from Texas Oncology will discuss current and emerging myeloma drug therapies, management of disease and treatment-related side effects, and emotional aspects and support of myeloma. For more information, visit the LLS Web site.
Racial Disparities In Multiple Myeloma: Its Effects On The African-American Community – The Multiple Myeloma Research Foundation (MMRF) will hold a myeloma workshop on January 13, 2009, from 5:30 p.m. to 9 p.m. at the Hyatt Regency McCormick Place in Chicago. The meeting’s agenda is designed primarily to educate general practitioners and other health care professionals who treat patients with multiple myeloma. For more information, visit the MMRF Web site.
The Road To Recovery: Emerging Therapies In Blood Cancers – The Leukemia & Lymphoma Society (LLS) will hold a dinner program on January 15, 2009, from 5:30 p.m. to 7:30 p.m. at Tin Angel restaurant in Nashville, TN. Guest speaker Dr. Ian W. Flinn, Director of Hematologic Malignancies Research at the Sarah Cannon Research Institute, will speak about the process of new drug discovery, research, and approval for treatment; recent and ongoing advances in blood cancer treatments; and selecting a clinical trial as a possible treatment option. For more information, visit the LLS Web site.
Related Articles:
- Stem Cell Transplantation May Be Underutilized In Multiple Myeloma Patients In Their 80s
- Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2018)
- Common Measures Of Heart And Blood Vessel Health May Predict Risk Of Heart-Related Side Effects During Treatment With Kyprolis
- Nelfinavir-Velcade Combination Very Active In Advanced, Velcade-Resistant Multiple Myeloma
- Adding Clarithromycin To Velcade-Based Myeloma Treatment Regimen Fails To Increase Efficacy While Markedly Increasing Side Effects